@article{QIMS18810,
author = {Menglong Zhao and Lili Dong and Zhuang Liu and Shuohui Yang and Weizhong Wu and Jiang Lin},
title = { In vivo fluorescence imaging of hepatocellular carcinoma using a novel GPC3-specific aptamer probe},
journal = {Quantitative Imaging in Medicine and Surgery},
volume = {8},
number = {2},
year = {2018},
keywords = {},
abstract = {Background: Glypican-3 (GPC3) is highly expressed in most of the hepatocellular carcinomas (HCCs), even in small HCCs. It may be used as a potential biomarker for early detection of HCC. The aptamer is a promising targeting agent with unique advantages over antibody. This study was to introduce a novel GPC3 specific aptamer (AP613-1), to verify its specific binding property in vitro, and to evaluate its targeting efficiency in vivo by performing near-infrared (NIR) fluorescence imaging on an HCC xenograft model.
Methods: AP613-1 was generated from the systematic evolution of ligands by exponential enrichment. Flow cytometry and aptamer-based immunofluorescence imaging were performed to verify the binding affinity of AP613-1 to GPC3 in vitro. NIR Fluorescence images of nude mice with unilateral (n=12) and bilateral (n=4) subcutaneous xenograft tumors were obtained. Correlation between the tumor fluorescence intensities in vivo and ex vivo was analyzed.
Results: AP613-1 could specifically bind to GPC3 in vitro. In vivo and ex vivo tumors, fluorescence intensities were in excellent correlation (P},
issn = {2223-4306}, url = {https://qims.amegroups.org/article/view/18810}
}